EE200100235A - cGMP PDE-5 inhibiitorit sisaldavad kontrollitud vabanemisega farmatseutilised formulatsioonid - Google Patents

cGMP PDE-5 inhibiitorit sisaldavad kontrollitud vabanemisega farmatseutilised formulatsioonid

Info

Publication number
EE200100235A
EE200100235A EEP200100235A EEP200100235A EE200100235A EE 200100235 A EE200100235 A EE 200100235A EE P200100235 A EEP200100235 A EE P200100235A EE P200100235 A EEP200100235 A EE P200100235A EE 200100235 A EE200100235 A EE 200100235A
Authority
EE
Estonia
Prior art keywords
inhibitor
controlled release
pharmaceutical formulations
formulations containing
release pharmaceutical
Prior art date
Application number
EEP200100235A
Other languages
English (en)
Inventor
King Elizabeth
James Macrae Ross
Original Assignee
Pfizer Research And Development Company, N.V./S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200100235(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9823192.1A external-priority patent/GB9823192D0/en
Priority claimed from GBGB9825117.6A external-priority patent/GB9825117D0/en
Priority claimed from GBGB9826392.4A external-priority patent/GB9826392D0/en
Application filed by Pfizer Research And Development Company, N.V./S.A. filed Critical Pfizer Research And Development Company, N.V./S.A.
Publication of EE200100235A publication Critical patent/EE200100235A/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200100235A 1998-10-23 1999-10-04 cGMP PDE-5 inhibiitorit sisaldavad kontrollitud vabanemisega farmatseutilised formulatsioonid EE200100235A (et)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9823192.1A GB9823192D0 (en) 1998-10-23 1998-10-23 Pharmaceutical formulations
GBGB9825117.6A GB9825117D0 (en) 1998-11-16 1998-11-16 Pharmaceutical formulations
GBGB9826392.4A GB9826392D0 (en) 1998-11-27 1998-11-27 Pharmaceutical formulations
PCT/IB1999/001619 WO2000024383A1 (en) 1998-10-23 1999-10-04 Controlled-release pharmaceutical formulations containing a cgmp pde-5 inhibitor

Publications (1)

Publication Number Publication Date
EE200100235A true EE200100235A (et) 2002-08-15

Family

ID=27269526

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100235A EE200100235A (et) 1998-10-23 1999-10-04 cGMP PDE-5 inhibiitorit sisaldavad kontrollitud vabanemisega farmatseutilised formulatsioonid

Country Status (44)

Country Link
US (1) US6964780B1 (et)
EP (1) EP1123088B1 (et)
JP (1) JP2002528408A (et)
KR (1) KR20010075659A (et)
CN (1) CN1324233A (et)
AP (1) AP2001002125A0 (et)
AT (1) ATE340562T1 (et)
AU (1) AU756509B2 (et)
BG (1) BG65323B1 (et)
BR (1) BR9914718A (et)
CA (1) CA2348086C (et)
CO (1) CO5160262A1 (et)
CR (1) CR6326A (et)
CY (1) CY1106239T1 (et)
CZ (1) CZ20011427A3 (et)
DE (1) DE69933383T2 (et)
DK (1) DK1123088T3 (et)
DZ (1) DZ2923A1 (et)
EA (1) EA004068B1 (et)
EE (1) EE200100235A (et)
ES (1) ES2272082T3 (et)
GT (1) GT199900184A (et)
HK (1) HK1041818A1 (et)
HR (1) HRP20010285A2 (et)
HU (1) HUP0104318A3 (et)
ID (1) ID28232A (et)
IL (1) IL141764A (et)
IS (1) IS5865A (et)
MA (1) MA26700A1 (et)
MX (1) MXPA01004011A (et)
MY (1) MY130727A (et)
NO (1) NO20011933L (et)
NZ (1) NZ510275A (et)
OA (1) OA11664A (et)
PA (1) PA8484301A1 (et)
PE (1) PE20001286A1 (et)
PL (1) PL195789B1 (et)
PT (1) PT1123088E (et)
SK (1) SK286473B6 (et)
TR (1) TR200101103T2 (et)
TW (1) TW577756B (et)
UA (1) UA67802C2 (et)
UY (1) UY25765A1 (et)
WO (1) WO2000024383A1 (et)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1049695E (pt) * 1997-11-12 2002-07-31 Bayer Ag Imidazotriazinonas 2-fenil substituidas enquanto inibidores de fosfodiesterase
KR20070051953A (ko) 1998-11-02 2007-05-18 엘란 코포레이션, 피엘씨 다입자 변형 방출 조성물
HU230828B1 (en) 1999-10-29 2018-08-28 Euro Celtique Sa Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
NZ524572A (en) * 2000-09-06 2004-08-27 Tanabe Seiyaku Co Oral compositions comprising phosphodiesterase inhibitors ( PDE inhibitor )and an acidic substance such as fumaric acid with improved drug efficacy due to decrease solubility in neutral and alkaline regions
CN101317825A (zh) 2000-10-30 2008-12-10 欧罗赛铁克股份有限公司 控释氢可酮制剂
KR100750554B1 (ko) * 2001-02-15 2007-08-20 다나베 세이야꾸 가부시키가이샤 구강 내 속붕괴성 정제
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
ITMI20020515A1 (it) * 2002-03-12 2003-09-12 Jagotec Ag Sistema per il rilasco controllato di uno o piu' principi attivi
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
SI1750766T1 (sl) 2004-05-11 2013-11-29 Emotional Brain B.V. Farmacevtske formulacije in njihove uporabe pri zdravljenju spolne disfunkcije pri Ĺľenskah
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
GB0421121D0 (en) * 2004-09-22 2004-10-27 Natrocell Technologies Ltd Composite rodenticide
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
US20090118211A1 (en) * 2005-06-27 2009-05-07 Daniel Drai Compositions and Methods for Enhancement of Sexual Function
US8227476B2 (en) 2005-08-03 2012-07-24 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
US20090186896A1 (en) * 2005-09-29 2009-07-23 Bayer Healthcare Ag PDE Inhibitors and Combinations Thereof for the Treatment of Urological Disorders
JP2009513604A (ja) 2005-10-29 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
JP2009541443A (ja) 2006-06-30 2009-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 尿失禁及び関連疾患の治療のためのフリバンセリン
KR20090042967A (ko) 2006-08-14 2009-05-04 베링거 인겔하임 인터내셔날 게엠베하 플리반세린 제형 및 이의 제조방법
EA200900270A1 (ru) 2006-08-25 2009-08-28 Бёрингер Ингельхайм Интернациональ Гмбх Системы регулируемого высвобождения и способ их приготовления
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
US20080226715A1 (en) * 2007-03-16 2008-09-18 Albert Cha Therapeutic compositions and methods
WO2008151734A1 (en) * 2007-06-13 2008-12-18 Bayer Schering Pharma Aktiengesellschaft Pde inhibitors for the treatment of hearing impairment
UY31335A1 (es) 2007-09-12 2009-04-30 Tratamiento de sintomas vasomotores
US20110033506A1 (en) * 2008-02-08 2011-02-10 Adel Penhasi Combination dosage form of low-dose modafinil and low-dose sildenafil
EP2374460A4 (en) * 2008-12-12 2013-08-21 Rhein Siegfried Sa De Cv SILDENAFIL COMPOSITION WITH PULSED RELEASE AND METHOD FOR PRODUCING THIS COMPOSITION
KR101004205B1 (ko) * 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
EA015250B9 (ru) * 2010-11-19 2013-10-30 Тева Фармасьютикал Индастриз, Лтд. Таблетка силденафила, обеспечивающая модифицированную фармакокинетику, и способ ее изготовления
SG10201606751XA (en) 2011-05-13 2016-10-28 Eb Ip Hybritabs B V Drug Delivery System
US20140328911A1 (en) * 2011-07-22 2014-11-06 Pom Wonderful. Llc Compositions comprising pomegranate polyphenols in combination with erectile dysfunction-treating compounds, and methods of treating erectile dysfunction therewith
WO2017168174A1 (en) * 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CN113995727B (zh) * 2021-11-08 2023-04-07 山东鲁抗医药股份有限公司 一种5型磷酸二酯酶抑制剂片剂及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3952741A (en) 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
JPS54119021A (en) * 1978-03-06 1979-09-14 Nippon Kayaku Co Ltd Carcinostatic agent
CH648754A5 (en) * 1979-08-16 1985-04-15 Ciba Geigy Ag Pharmaceutical slow release tablet
JPS5748908A (en) * 1980-09-08 1982-03-20 Kyorin Pharmaceut Co Ltd Prolonged release type nicomol pharmaceutical
FR2624732B1 (fr) 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
MC2025A1 (fr) * 1988-04-20 1990-04-25 Asta Pharma Ag Medicament contenant de l'azelastine et capable de liberer celle-ci de facon controlee
IT1229856B (it) * 1989-04-20 1991-09-13 Recordati Chem Pharm Compresse a rilascio controllato contenenti flavossato.
US5474784A (en) 1990-03-02 1995-12-12 British Technology Group Limited Dispensing device
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
PT621032E (pt) * 1993-04-23 2001-01-31 Novartis Ag Dispositivo de distribuicao de libertacao controlada de farmaco
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US5656629A (en) * 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
AU2976897A (en) * 1996-06-18 1998-01-07 Otsuka Pharmaceutical Co., Ltd. Multiple-unit type prolonged action drug preparation
JPH1067657A (ja) * 1996-06-18 1998-03-10 Otsuka Pharmaceut Co Ltd マルチプルユニット型持続性製剤
KR20000069899A (ko) * 1997-01-06 2000-11-25 디. 제이. 우드, 스피겔 알렌 제이 속방성 및 미각 차폐성 약제학적 용량 형태
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6277884B1 (en) * 1998-06-01 2001-08-21 Nitromed, Inc. Treatment of sexual dysfunction with N-hydroxyguanidine compounds
DK1109814T3 (da) * 1998-09-04 2004-08-02 Ortho Mcneil Pharm Inc 5-Heterocyclylpyrazolo[4,3-d]pyrimidin-7-oner til behandling af mandlig erektil dysfunktion

Also Published As

Publication number Publication date
EP1123088A1 (en) 2001-08-16
OA11664A (en) 2005-01-07
GT199900184A (es) 2001-04-14
HK1041818A1 (zh) 2002-07-26
UY25765A1 (es) 2001-08-27
EP1123088B1 (en) 2006-09-27
IL141764A (en) 2008-06-05
PL195789B1 (pl) 2007-10-31
BR9914718A (pt) 2001-07-10
NO20011933L (no) 2001-06-25
JP2002528408A (ja) 2002-09-03
CA2348086C (en) 2007-01-23
UA67802C2 (uk) 2004-07-15
MA26700A1 (fr) 2004-12-20
DE69933383D1 (de) 2006-11-09
TW577756B (en) 2004-03-01
IL141764A0 (en) 2002-03-10
PA8484301A1 (es) 2000-09-29
ES2272082T3 (es) 2007-04-16
DK1123088T3 (da) 2007-01-02
CN1324233A (zh) 2001-11-28
DZ2923A1 (fr) 2004-03-01
BG65323B1 (bg) 2008-02-29
SK5192001A3 (en) 2002-09-10
CY1106239T1 (el) 2011-06-08
HUP0104318A2 (hu) 2002-03-28
NO20011933D0 (no) 2001-04-19
AP2001002125A0 (en) 2001-04-04
EA004068B1 (ru) 2003-12-25
MXPA01004011A (es) 2003-03-10
TR200101103T2 (tr) 2001-09-21
AU5878799A (en) 2000-05-15
KR20010075659A (ko) 2001-08-09
PL347476A1 (en) 2002-04-08
HUP0104318A3 (en) 2003-12-29
AU756509B2 (en) 2003-01-16
IS5865A (is) 2001-02-27
DE69933383T2 (de) 2007-02-01
BG105465A (bg) 2001-12-29
CR6326A (es) 2004-02-23
WO2000024383A1 (en) 2000-05-04
CZ20011427A3 (cs) 2001-10-17
CA2348086A1 (en) 2000-05-04
CO5160262A1 (es) 2002-05-30
PT1123088E (pt) 2007-01-31
HRP20010285A2 (en) 2002-06-30
EA200100298A1 (ru) 2001-08-27
SK286473B6 (sk) 2008-11-06
ID28232A (id) 2001-05-10
PE20001286A1 (es) 2000-11-22
ATE340562T1 (de) 2006-10-15
US6964780B1 (en) 2005-11-15
NZ510275A (en) 2003-07-25
MY130727A (en) 2007-07-31

Similar Documents

Publication Publication Date Title
EE200100235A (et) cGMP PDE-5 inhibiitorit sisaldavad kontrollitud vabanemisega farmatseutilised formulatsioonid
DK0922386T3 (da) Sammensætninger med reguleret frigivelse
DK0938345T3 (da) Vandbaseret farmaceutisk sammensætning
DK199801384A (da) Strålingshærdelige cyanoacrylat-holdige sammensætninger
ID23299A (id) Formulasi-formulasi farmasi
ID30031A (id) Formulasi-formulasi agrokimia
ID23546A (id) Formulasi-formulasi ziprasidon
NO942477L (no) Opioide formuleringer med forlenget, regulert frigivelse
NO20004240L (no) Formuleringer
IS2004B (is) Lyfjasamsetningar sem innihalda vorikónasól
ATE252386T1 (de) Galantamin-zusammensetzung mit gesteuerter freisetzung
NO20012636D0 (no) Kontrollert frigivelsesformulering som omfatter GNRH-II
EE200100134A (et) Kiiresti vabastav tablett
BR9701304A (pt) Formulação de liberação prolongada
PT973527E (pt) Formulacoes de libertacao prolongada de claritromicina
ATE224703T1 (de) Brauseformulierungen
NO20052635D0 (no) Kontrollert frigivelsesdepot formuleringer
MA24473A1 (fr) Formulations
DE60043447D1 (de) Zusammensetzungen mit kontrollierter freigabe enthaltend nimesulid
PT1130966E (pt) Formulacoes antiparasitarias
EE05020B1 (et) Glburiidi ravimkoostis
NO20002126L (no) Formulering med forlenget frigjøring
DE60103582D1 (de) Zusammensetzungen mit kontrollierter Freisetzung
IS6398A (is) Lyfjablöndur
ATE357237T1 (de) Formulierungen enthaltend cefuroxim-axetil